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ABSTRACT
We identified the specific role of vaccinia-related kinase 1 (VRK1) in the 
progression of hepatocellular carcinoma (HCC) and evaluated its therapeutic and 
prognostic potential. VRK1 levels were significantly higher in HCC cell lines than 
a normal hepatic cell line, and were higher in HCC than non-tumor tissue. VRK1 
knockdown inhibited the proliferation of SK-Hep1, SH-J1 and Hep3B cells; moreover, 
depletion of VRK1 suppressed HCC tumor growth in vivo. We also showed that VRK1 
knockdown increased the number of G1 arrested cells by decreasing cyclin D1 and 
p-Rb while upregulating p21 and p27, and that VRK1 depletion downregulated 
phosphorylation of CREB, a transcription factor regulating CCND1. Additionally, we 
found that luteolin, a VRK1 inhibitor, suppressed HCC growth in vitro and in vivo, and 
that the aberrant VRK1 expression correlated with poor prognostic features of HCC. 
High levels of VRK1 were associated with shorter overall and disease-free survival 
and higher recurrence rates. Taken together, our findings suggest VRK1 may act as 
a tumor promoter by controlling the level of cell cycle regulators associated with 
G1/S transition and could potentially serve as a therapeutic target and/or prognostic 
biomarker for HCC.
INTRODUCTION
Liver cancer is the second leading cause of 
cancer-related death among males and the sixth most 
common cause of death among females, worldwide [1]. 
Hepatocellular carcinoma (HCC) accounts for 85% to 90% 
primary liver cancers [2]. Although therapeutic options 
for HCC have improved in recent years, incidences of the 
disease have remained high in Eastern and South-Eastern 
Asia and are increasing in the United States and Central 
Europe [1]. The major reason for unsuccessful treatment 
of HCC is resistance to conventional chemotherapy [3], 
and surgical resection and liver transplantation have 
limited applicability due to frequent tumor recurrence [4]. 
Undoubtedly, a better understanding of the mechanisms 
underlying HCC progression is crucial for effective 
treatment of the disease.
Vaccinia-related kinase 1 (VRK1) is a member of 
the Ser/Thr kinase family in mammals [3], and is involved 
in cell cycle progression, chromosome condensation, 
nuclear envelope breakdown and reassembly and the DNA 
damage response. VRK1 acts through phosphorylation of 
several substrates, including CRE binding protein, histone 
H3, barrier-to-autointegration factor and p53 [4–9]. VRK1 
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mediates p53 accumulation by increasing its stability 
through phosphorylation of Thr-18 within its mdm-2 
binding site [10, 11]. At the same time, VRK1 levels are 
downregulated by p53, forming autoregulatory loop [12]. 
This p53-induced downregulation of VRK1 is dependent 
on an autophagic pathway and protein degradation by 
lysosomes [13].
Emerging evidence suggests VRK1 plays an 
essential role in cancer progression [3]. For example, high 
levels of VRK1 mRNA have been detected in actively 
proliferating cells within fetal tissues and in several cancer 
cell lines [14]. In addition, VRK1 expression correlates 
positively with several proliferation markers in head-and-
neck squamous cell cancers and lung carcinomas [15, 16], 
and VRK1 levels tend to be elevated in lung cancer tissues 
in which p53 is mutated [16]. In breast cancer, VRK1 
depletion inhibits tumor growth and metastasis [17] and 
confers resistance to DNA-damaging agents [18], and it 
has been suggested that VRK1 is a potential therapeutic 
target and a prognostic marker for breast cancer [19, 20].
On the other hand, there have been few studies 
examining the precise role of VRK1 in the progression of 
HCC or its clinical association with HCC. In the present 
study, therefore, our aim was to determine the function 
of VRK1 within HCC tissues and cell lines. Our findings 
suggest that VRK1 enhances HCC cell proliferation by 
modulating the levels of regulators associated with G1/S 
transition and that VRK1 levels are much higher in HCC 
tissues than non-tumor tissues, and are associated with 
shorter overall and disease-free survival and a higher 
recurrence rate. Based on these findings, we propose that 
VRK1 could potentially serve as a therapeutic target and/
or a prognostic marker in HCC.
RESULTS
VRK1 is overexpressed in HCC cells and its 
depletion suppresses HCC cell proliferation  
in vitro
To identify the role of VRK1 in liver cancer, VRK1 
levels were examined in an immortalized hepatocyte cell 
line, THLE-2, and in six HCC cell lines, including SH-J1, 
SK-Hep1, Huh-7, Hep3B, HepG2 and SNU449. With the 
exception of Hep3B cells, which grow slower the other 
HCC cells, VRK1 levels were higher in HCC cells than 
THLE-2 cells (Fig. 1A and 1B). VRK1 expression is 
known to be enhanced in lung cancers expressing a mutant 
p53 and to be down-regulated by ectopic expression of 
wild-type p53 in lung cancer cells [16]. Therefore, to 
investigate why VRK1 levels are higher in HCC cells, 
we checked the levels and status of p53. p53 expression 
was relatively high in THLE-2, Huh-7 and SNU449 cells, 
but low in SH-J1, SK-Hep1, HepG2 and Hep3B cells 
(Fig. 1A and 1B). We found that there was not a detectable 
inverse correlation between p53 and VRK1 levels in the 
seven cell lines. We then examined VRK1 levels after 
transfecting SK-Hep1, SH-J1 and Hep3B cells with 
increasing amounts of pcDNA_p53 and the same amount 
of pCMV_VRK1-flag (Sup. 1A and 1B). As the level of 
p53 increased, the level of VRK1 expression declined in 
these cells (Sup. 1A and 1B). Thus an inverse relation 
was detected between the levels of VRK1 and ectopically 
expressed p53 (Sup. 1A and 1B).
The status of p53 in the tested HCC cell lines was 
examined previously and those findings are summarized in 
Table 1. p53 is wild-type in THLE-2, SH-J1, SK-Hep1 and 
HepG2 cells, but is mutated in Huh-7 and SNU449 cells, 
and null in Hep3 cells. As with p53 expression levels, there 
was no correlation between the status of p53 and VRK1 
levels in any of the seven cell lines (Fig. 1A and 1B). 
Additionally, because HBV infection is a major risk factor 
for HCC development, the association between HBV status 
and VRK1 expression was assessed in the seven cell lines, 
several of which are HBV-positive (Table 1). However, we 
found no significant correlation between VRK1 expression 
and HBV status .
To better understand the molecular function of 
VRK1 in HCC tumorigenesis, we transiently silenced 
VRK1 expression or overexpressed VRK1 in THLE-2 and 
HCC cell lines, after which we measured cell proliferation 
using WST-1 assays. Western blotting showed that VRK1 
was efficiently knocked down or overexpressed by 
transfection of a targeted siRNA or expression vector, 
respectively (Fig. 1C and 1D, upper panel). Significant 
reductions in proliferation were observed in HCC cell 
lines following VRK1 knockdown (P < 0.001), but not 
in THLE-2 cells (Fig. 1C, lower panel). Conversely, 
overexpression of VRK1 significantly enhanced the 
proliferation of SH-J1 and Hep3B cells (P < 0.001), but 
not SK-Hep1 cells (Fig. 1D, lower panel). To further 
evaluate the long-term effects of reducing VRK1 
expression on cellular proliferation, we performed as 
set of colony formation assays (Fig. 2E). Knocking 
down VRK1 expression reduced the size of all HCC cell 
colonies (P < 0.001), with the most dramatic effect on SK-
Hep1 cells, which normally express the highest level of 
VRK1 (19.86% ± 0.27), and the smallest effect on Hep3B 
cells, which normally express the lowest levels of VRK1 
(74.92% ± 6.98; Fig. 2E). By contrast, knocking down 
VRK1 had no significant effect on the size of THLE-2 cell 
colonies (97.16 ± 3.81; Fig. 2E and Sup. Fig. 2).
VRK1 depletion inhibits tumor growth in a 
xenograft mouse model
To investigate the contribution of VRK1 to 
tumor growth in vivo, we established SK-Hep1 cells 
expressing shRNA targeting VRK1 through transduction 
using a lentiviral vector. Two weeks after transduction, 
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Figure 1: Regulation of HCC cell growth by VRK1 in vitro. A. The levels of VRK1 in THLE-2 cells, an immortalized normal 
cell line, and six HCC cell lines were analyzed by Western blotting using actin as a loading control. B. Band intensities were measured 
by densitometry using Image J. VRK1 and p53 band intensities were normalized to those of actin. C. VRK1 levels were reduced in HCC 
and THLE-2 cells 48 h after transfection with VRK1 siRNA as judged by Western blot analysis. Cell proliferation after silencing VRK1 
expression was assessed with WST-1 assays 72 h after transfection. Cell proliferation (%) were calculated relative to that at the time of 
transfection, which was set to 100%. D. Cells were transfected with flag- or VRK1-flag-expressing vectors, and VRK1 level was analyzed 
by Western blotting 48 h after transfection. Increases of cell proliferation were significant in SH-J1 and Hep3B cells upon overexpression 
of VRK1, but not in SK-Hep1 cells. E. Colony formation assays were performed using HCC or THLE-2 cells transfected with control 
siRNA or VRK1 siRNA. Magnified image of a THLE-2 cell colony is shown in Supplementary Figure 2. Cells were grown for 10 days 
and stained with crystal violet (Left). Colonies were quantified by measuring the absorbance of extracted crystal violet at 595 nm (Right). 
(***p < 0.001; n.s., not significant)
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different knockdown efficiencies were observed with for 
independent shRNAs targeting different sequences of 
VRK1 (Fig. 2A, upper panel). Colony formation assays 
with stable cell lines (clones 1 and 3) showed efficient 
VRK1 knockdown and confirmed significant loss of 
colony forming ability (P < 0.001; Fig. 2A, middle and 
lower panel). Clone 1 expressing the lowest level of 
VRK1 displayed the most dramatic decrease in colony 
formation (4.73% ± 1.02, Fig. 2A, lower panel). After 3, 4, 
5 and 6 weeks of viral transduction, stable cell lines were 
subjected to Western blot analysis and colony formation 
assays to confirm the anti-tumor effect by sustained VRK1 
knockdown. Efficient knockdown and diminished colony 
formation were maintained in stable VRK1-deficient cells 
for least 6 weeks (Sup. Fig. 3A and 3B).
Once the stability of the VRK1 knockdown was 
confirmed, we injected cell lines stably expressing VRK1 
shRNA Clone 1 into the right flanks of nude mice and 
negative control shRNA into the left flanks. Tumor 
volumes were then determined every 2 weeks. Significant 
differences in volume between tumors expressing shVRK1 
and those expressing control shRNA were observed 
beginning 4 weeks after injection (P < 0.01; Fig. 2B), 
and at 8 weeks the mean volume of shVRK1-expressing 
tumors was 196.67 ± 52.40 mm3, while that of tumors 
expressing control shRNA was 324.61 ± 68.95 mm3 
(Fig. 2B and 2C). In addition, the weights of shVRK1-
expressing tumors were correspondingly lower than the 
weights of tumors expressing control shRNA 
(111.67 ± 21.08 mg vs. 164.17 ± 37.17 mg; Fig. 2D).
To confirm the efficiency of the sustained VRK1 
knockdown during tumor growth in vivo, Western blotting 
was performed using tumor tissues collected from each 
group of mice. Significant downregulation of VRK1 
was observed in the tumor tissues derived from VRK1 
knockdown cells, as expected (Fig. 2E). Additionally, 
immunohistochemical staining for Ki-67, a general marker 
of proliferating cells, showed significantly fewer Ki-67-
positive cells in tumors expressing shVRK1 (29.75 cells 
± 78) than in those expressing negative control shRNA 
(67.5 cells ± 15.77; Fig. 2F).
VRK1 depletion increases the G1 arrest in 
HCC cells by controlling the level of cell cycle 
regulators
Anti-growth effects are generally explained as 
the result of cell cycle disruption and/or apoptosis or 
senescence induction. We explored the effects of VRK1 
depletion on induction of apoptosis and cell cycle 
regulation. Induction of apoptosis was measured using 
the PI-Annexin V double staining method 24 h after 
transfection (Sup. 4A and 4B). No significant induction of 
apoptosis was detected in HCC cells following depletion 
of VRK1 (Sup. 4A and 4B). On the other hand, 24 h after 
transfection with VRK1 siRNA, the numbers of G1 phase 
gated cells were significantly higher in SK-Hep1 and 
SH-J1 than control cells, whereas the numbers of S phase 
gated cells were lower (Fig. 3A and 3B). By contrast, 
no significant changes in cell cycle populations were 
found in Hep3B and THLE-2 cells after VRK1 depletion 
in an asynchronous cell population (Fig. 3A and 3B). 
Nocodazole arrests cell cycle progression in G2/M phase 
by disrupting mitotic spindles [21], and so was used to 
assess G1 arrest induced by VRK1 depletion. Following 
nocodazole treatment, the majority of control cells were 
synchronized at G2/M phase, whereas VRK1-depleted 
cells could not be synchronized at G2/M phase at any time 
during the time-course of the experiment (Fig. 3C and 3D). 
Instead, most VRK1-depleted cells were at G1 phase 
(Fig. 3C and 3D). The largest G1 phase gated cell fraction 
was among VRK1-depleted SK-Hep1 cells (40.06% at 
15 h, 37.79% at 17.5 h, 39.45% at 20 h; Fig. 3C and  3D), 
followed by VRK1-depleted SH-J1 cells (36.28% at 
15 h, 36.20% at 17.5 h, 35.74% at 20 h; Fig. 3C and 3D). 
The smallest G1 phase gated cell fraction was among 
VRK1-depleted Hep3B cells (18.47% at 15 h, 12.67 
at 17.5 h, 7.84% at 20 h; Fig. 3C and 3D). Following 
nocodazole treatment, the size of the G1 phase gated cell 
fraction remained unchanged over the observation time-
course in VRK1-depleted SK-Hep1 and SH-J1 cells, but it 
gradually declined in VRK1-depleted Hep3B cells (18.47% 
at 15 h, 12.67% at 17.5 h and 7.87% at 20 h; 3C and 3D).
Table 1: HBV and p53 status of HCC cells
HBV p53
THLE-2 Immortalized normal cell
SK-Hep1 Negative [45] WT [11]
SH-J1 Negative [37] WT [46]
Hep3B Positive [45] Null [11, 47]
Huh-7 Negative [48] Mutated [11]
HepG2 Negative [45] WT [11]
SNU449 Positive [49] Mutated [11]
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Figure 2: Growth of HCC tumors after VRK1 depletion in vivo. A. SK-Hep1 cells were transduced with a lentiviral vector 
encoding VRK1- or negative control (NC)-shRNA sequences. Five lentiviral particles (Clones 1–5) targeted to different sequences in 
the VRK1 gene were used and the efficiencies of the VRK1 depletion were compared by Western blotting 1 week after transduction 
(upper panel). Colony formation assays were performed using stably transduced SK-Hep1 cells (middle panel). Colonies were quantified 
by measuring the absorbance of extracted crystal violet at 595 nm (lower panel). B. 5 × 106 cells were injected subcutaneously. Tumor 
sizes were measured in 10 mice every 2 weeks after injection, and are shown as means ± SEM (upper panel). C. Photographs of mice 
were taken after sacrifice. NC (blue arrow) and shVRK1 (red arrow) indicate the flanks injected with SK-Hep1 cells transduced with NC 
shRNA or VRK1 shRNA (upper panel). Tumors were collected from the sacrificed mice and their sizes compared (lower panel). D. Tumor 
weights were measured after sacrifice of mice, and are shown as means ± SEM. E. Levels of VRK1 in injected tumors were analyzed by 
Western blotting after sacrifice. F. Levels of Ki-67 and VRK1 were assessed immunohistochemically using a confocal microscope, and  
Ki-67-positive cells were counted in randomly obtained images. Scale bar indicates 50 μm. (***p < 0.001; **p < 0.01)
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We next assessed the levels of cell cycle regulators 
associated with G1/S transition in VRK1-depleted cells. 
Effective silencing of VRK1 led to downregulation of 
cyclin D1 involved in G1/S transition in HCC cell lines 
(Fig. 4A). Rb protein is the substrate for cyclin D1 and 
cdk 4/6 complex, and their phosphorylation is the crucial 
step for initiating G1/S transition [22]. As we expected, 
p-Rb795 and p-Rb807/811 levels were reduced by VRK1 
depletion in HCC cells, except in Hep3B cells, which 
do not express Rb protein (Fig. 4A). Furthermore, levels 
of p27 and p21, which act as cell cycle inhibitors by 
suppressing various cyclin/cdk complexes, were increased 
by VRK1 depletion (Fig. 4A). Because the p21 levels are 
known to be increased by p53 [23], and p53 is stabilized 
by VRK1 [10], we checked p53 levels to be increased 
or decreased in VRK1-depleted HCC cells. However, 
no significant change of p53 level was observed in VRK1-
depleted HCC cells (Fig. 4A). Our group previously 
showed that cyclin D1 was upregulated by VRK1 through 
phosphorylation (activation) of CREB, which in turn 
activates cyclin D1 transcription [8]. We therefore also 
checked levels of the p-CREB and CREB proteins and 
cyclin D1 mRNA. We found that p-CREB levels were 
reduced by VRK1 inactivation in HCC cells (Fig. 4B and 
4C), and there was a corresponding reduction the level of 
cyclin D1 mRNA in VRK1-depleted HCC cells (Fig. 4D).
Figure 3 (continued): FACS analysis of VRK1-depleted HCC cells. A. SK-Hep1, SH-J1, Hep3B and THLE-2 cells were 
transfected with control or VRK1 siRNAs and grown for 24 h, after which they were stained with propidium iodide (PI) and 
subjected to FACS analysis. The number of HCC cells at G1, S and G2/M phase was quantified. The Modifit program was 
used for data analysis. B. The percentages of cells at G1, S and G2/M phase are indicated in the histogram.
( Continued)
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Figure 3: C. Cells were incubated with 50 ng/ml nocodazole 1 day after transfection. After the indicated incubation times  
(15 h, 17.5 h and 20 h) with nocodazole, the cells were stained with PI and subjected to FACS analysis. D. The percentages of 
cells treated with nocodazole at G1, S and G2/M phase are indicated in the histogram. Three independent experiments were 
performed and representative FACS data are shown.
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Luteolin, a VRK1 inhibitor, reduces HCC 
growth
Luteolin is a natural flavonoid (Fig. 5A) originating 
from plants that has also been shown to inhibit VRK1. 
Because we found that VRK1 depletion retarded growth 
of HCC cells, we tested whether a similar retardation 
could be achieved by pharmacological blockade VRK1. 
When HCC cells were treated with various concentrations 
of luteolin, HCC cell proliferation was significantly 
Figure 4: Levels of cell cycle regulators in VRK1-depleted HCC cells. A. Levels of cell cycle-related proteins and VRK1 were 
analyzed by Western blotting. Band intensities were quantified by densitometry using Image J and normalized to those of actin serving as 
the loading control. The intensities were calculated relative to those of the control, which were set to 1.0. Blue and red numbers indicate 
values lower than 0.8 and higher than 1.2, respectively. B. Levels of p-CREB and CREB proteins were confirmed by Western blotting. 
C. Relative levels (p-CREB/CREB) are shown in the histogram. Band intensities were measured by densitometry using Image J, and 
the intensities of the CREB and p-CREB band were normalized to that of the actin band. D. Levels of cyclin D1 mRNA in HCC cells 
transfected with siRNAs are indicated in the histogram. Cells for Western blotting and RT-PCR were harvested 24 h after transfection. Data 
shown are representative blots from three independent experiments. (**p < 0.01)
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reduced in a concentration-dependent manner (Fig. 5B). 
Relative cell proliferation at 40 and 50 μM luteolin was 
71.70% ± 1.86 and 63.34% ± 6.58 for SK-Hep1 cells 
(P < 0.01 and P < 0.001), 84.71% ± 4.63 and 73.19% 
± 3.79 for SH-J1 cells (P < 0.001), and 71.18% ± 4.96 
and 63.60% ± 6.72 for Hep3B cells (P < 0.001; Fig. 5B). 
Luteolin has also been shown to induce apoptosis in 
several types of cancers [24]. We therefore tested the 
ability of luteolin to induce apoptosis in HCC cells. 
We found that treatment with luteolin significantly and 
concentration-dependently increased the incidence of 
apoptosis among SK-Hep1 and SH-J1 cells (Fig. 5C and 
Sup. 5A). In addition, a minor induction of apoptosis was 
detected in Hep3B cells treated with luteolin (Fig. 5C and 
Sup. 5A).
To confirm the anti-tumor effect of VRK1 inhibition 
in vivo, luteolin was administered after subcutaneous 
injection of SK-Hep1 cells into flanks of nude mice. Tumor 
Figure 5: Effect of the VRK1 inhibitor luteolin on HCC cell proliferation and apoptosis. A. Chemical structure of luteolin. 
B. Concentration-dependent effects of luteolin on cell proliferation were assessed using WST-1 assays after addition of the indicated 
concentrations of luteolin. SK-Hep1, SH-J1 and Hep3B cells were treated for 24 h with luteolin in the growth medium, after which the 
culture medium was replaced with one containing WST-1 reagent to measure cell proliferation. HCC cell proliferation was normalized to 
that of cells treated with vehicle only. C. Concentration-dependent effects of luteolin on apoptosis were assessed using the PI and Annexin 
V double staining method 24 h after addition of luteolin. FITC Annexin V-positive, PI-negative cells were defined as early apoptotic, 
and FITC Annexin V-positive, PI-positive cells were defined as late apoptotic in the histograms. Raw flow cytometry data are shown in 
Supplementary Figure 5. Data shown are representative histograms from three independent experiments. (***p < 0.001)
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volumes were then determined weekly after the injection of 
luteolin. Significant differences in tumor volume between 
the luteolin-treated group (143.06 ± 26.03 mm3) and the 
vehicle-treated group (344.47 ± 62.03 mm3) were observed 
5 weeks after luteolin injection (P < 0.05; Fig. 6A). The 
resulting tumor sizes in mice injected with luteolin were 
smaller than those injected with vehicle (Fig. 6B and 6C). 
Correspondingly, tumor weights were smaller in tumors 
treated with luteolin (116 ± 15.77 mg) than in those treated 
with vehicle (193 ± 22.80 mg; Fig. 6D). To assess the 
toxicity of luteolin to mice, samples of liver tissue from 
vehicle- and luteolin-treated mice were subjected to H&E 
staining. No histological difference in the liver tissue was 
observed between the two groups (Fig. 6E).
Figure 6: Effect of luteolin on tumor growth in vivo. A. SK-Hep1 cells (1 × 107) were injected subcutaneously. Vehicle or luteolin 
(20 mg/kg/d) was injected intraperitoneally into mice daily for 2 weeks after inoculation. Tumor size was measured in 4 mice weekly 
after starting the injections, and are shown as means ± SEM. B. Photographs of mice treated with vehicle or luteolin taken after sacrifice.  
C. Tumors were collected from the sacrificed mice, and their sizes were compared. D. Tumor weights were measured after sacrifice of mice, 
and are shown as means ± SEM. E. Histological differences in liver tissues from mice treated with vehicle or luteolin were compared using 
H&E staining. Representative photomicrographs of tumor sections taken at a magnification of 400x. Scale bar indicates 50 μm. (*p < 0.05)
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High VRK1 expression is associated with a poor 
prognosis of HCC patients
The fact that VRK1 might be oncogenic in HCC led 
us to hypothesize that VRK1 could be strongly expressed 
in HCC patients’ tissues and its expression predictive of 
a poor prognosis. To test our hypothesis, VRK1 levels 
were assessed immunohistochemically in 88 HCC 
specimens. The clinicopathological characteristics of the 
88 HCC patients were cataloged (Sup. Table 1), and the 
intensity of the VRK1 staining in each sample assigned a 
score of 0 (negative staining, Fig. 7A), 1 (<5% staining, 
Fig. 7B), 2 (<25% staining, Fig. 7C) or 3 (25–50% 
staining, Fig. 7D). VRK1 levels were markedly higher 
in tumors than in non-tumor specimens (0.0000 versus 
0.3182; mean 2-ΔCT values, P < 0.0001). A representative 
immunohistochemical image of VRK1 in tumor and non-
tumor samples is shown in Fig. 7E. A higher number of 
VRK1-positive cells was found in the tumor region than 
the adjacent non-tumor region (Fig. 7E).
Figure 7: VRK1 expression in non-tumor and HCC tissue. A–D. VRK1-stained tumor tissues were assigned a score of 0 (A, 
negative staining), 1 (B, < 5% staining), 2 (C, < 25% staining) or 3 (D, 25–50% staining). E. Levels of VRK1 were compared between 
non-tumor and HCC tissue using immunohistochemistry. Representative images of VRK1-stained tissues were obtained at a magnification 
of 200x. Scale bar indicates 50 μm.
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We investigated the association between the VRK1 
level and prognosis of HCC patients. Patients were 
classified as VRK1-high and VRK1-low based on 
receiver operating characteristic (ROC) curve analysis 
using the highest area under the curve (AUC) that could 
significantly discriminate between patients with good 
and poor prognoses with respect to overall survival (OS). 
HCCs with IHC intensities of 0–1 and 2–3 were classified 
as VRK1-low and VRK1-high groups, respectively. 
Kaplan-Meier survival analysis indicated that median 
recurrence times in patients with high and low VRK1 
levels were 12.85 and 30.64 months, respectively 
(P = 0.0356; Fig. 8A). The VRK1-high group also 
displayed shorter OS (VRK1-high, 36.43 months; 
VRK1-low, 53.92 months), but the differences were less 
significant (P = 0.0734; Fig. 8B). The median disease-
free survival (DFS) was similar to median recurrence 
time, with borderline significance (P = 0.0555; Fig. 8C). 
Additionally, we used Fisher’s exact test to examine the 
association between VRK1 levels and clinicopathological 
characteristics. With the exception of age, there were no 
significant differences in clinicopathological features, 
including HBV and HCV status (P = 1.0), between the 
VRK1-high and VRK1-low groups, (Sup. Table 2). The 
VRK1-high group tended to be ≥ 55 years and VRK1-low 
group to be < 55 years, with borderline of significance 
(P = 0.051).
The prognostic significance of the VRK1 level 
was further confirmed in a Cox regression analysis. In a 
univariate analysis, the AFP level was related to significant 
risk for both OS and DFS, and liver cirrhosis was the only 
significant prognostic factor for OS (Table 2). Common 
prognostic factors for recurrence, OS and DFS were 
Edmondson grade, tumor size, tumor stage, vascular 
invasion and tumor number (Table 2). Interestingly, a high 
VRK1 level was a significant risk factor for recurrence 
(P = 0.041), but not as much for OS and DFS (Table 2). 
To further confirm VRK1 as an independent prognostic 
marker for recurrence of HCC, multivariate Cox analysis 
was performed with the aforementioned significant risk 
variables for recurrence (Table 3). The multivariate Cox 
model suggested that VRK1 could be an independent 
prognostic factor for recurrence with borderline 
significance (P = 0.056; Table 2).
Figure 8: Prognostic value of VRK1 expression in patients with HCC. A–C. Kaplan-Meier analysis based on VRK1 levels in 
HCC patients. The probabilities of recurrence (A), overall survival (B) and disease-free survival (C) among patients are shown.
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DISCUSSION
The present study was conducted to elucidate the 
role played by VRK1 in HCC cell lines and patient tissues, 
and the results highlight the oncogenic role of VRK1 in 
HCC. VRK1 regulates the cell cycle by controlling levels 
of effector proteins associated with G1/S transition. VRK1 
levels, which were higher in HCC than healthy tissue, 
were associated with shorter OS and DFS and a higher 
recurrence rate in HCC patients.
Depletion of VRK1 using siRNA and shRNA 
suppressed the growth of HCC cells significantly. 
Consistent with that finding, VRK1 depletion was 
previously shown to suppress cell proliferation in 
Table 2: Univariate Cox analysis
Variable
Univariate analysis Recurrence Univariate analysis OS Univariate analysis DFS
Hazard Ratio (95% 
CI)
P value Hazard Ratio 
(95% CI)
P value Hazard Ratio 
(95% CI)
P value
Age(<55 years vs  
≥55 years)
1.06(0.62–1.82) 0.818 1.2(0.69–2.08) 0.526 1.21(0.73–2) 0.466
Gender(male vs 
female) 1.16(0.66–2.04) 0.615 1.03(0.57–1.85) 0.933 1.13(0.66–1.93) 0.649
Edmondson grade 
(I,II vs III,IV) 1.94(1.14–3.32) 0.015 2.12(1.22–3.69) 0.008 1.81(1.09–3) 0.021
HBV(absent vs present) 1.1(0.59–2.06) 0.768 1.2(0.63–2.3) 0.579 1.06(0.59–1.91) 0.834
HCV(absent vs present) 0.96(0.38–2.42) 0.935 1.27(0.54–2.99) 0.584 1.25(0.57–2.76) 0.58
AFP level(< 100 ng/ml 
vs ≥ 100 ng/ml)
1.73(0.97–3.09) 0.063 2.43(1.29–4.6) 0.006 1.81(1.05–3.13) 0.034
Liver cirrhosis 
(absent vs present) 0.89(0.51–1.59) 0.703 1.78(1.02–3.13) 0.043 1.24(0.74–2.08) 0.412
Tumor size 
(≤ 5 cm vs > 5 cm)
2.62(1.49–4.61) 0.001 2.25(1.27–3.98) 0.006 2.1(1.25–3.52) 0.005
Tumor stage 
(I,II vs III,IV) 3.23(1.87–5.57) < 0.001 3.51(1.99–6.18) < 0.001 2.71(1.61–4.58) < 0.001
Vascular Invasion 
(absent vs present) 3.84(2.01–7.34) < 0.001 4.46(2.21–9.01) < 0.001 3.22(1.8–5.74) < 0.001
Tumor number 
(Single vs Multi) 2.95(1.71–5.08) < 0.001 3.98(2.26–7.02) < 0.001 3.03(1.81–5.06) < 0.001
VRK1(0,1 vs 2,3) 2.31(1.03–5.15) 0.041 2.06(0.92–4.62) 0.08 2.14(0.96–4.75) 0.062
* Data in which p < 0.05 are highlighted in bold.
Table 3: Multivariate Cox analysis
Variable Multivariate analysis Recurrence
Hazard Ratio(95% CI) P value
Edmondson grade (I,II vs III,IV) 1 (0.55–1.81) 0.999
Tumor size (≤5 cm vs >5 cm) 1.7 (0.9–3.19) 0.1
Tumor stage (I,II vs III,IV) 1.04 (0.34–3.22) 0.946
Vascular Invasion (absent vs present) 2.77 0.009
Tumor number (Single vs Multi) 2.29 (0.81–6.45) 0.118
VRK1 (0,1 vs 2,3) 2.37 (0.98–5.76) 0.056
* Data in which p < 0.05 are highlighted in bold.
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WS1 fibroblastic cells and lung cancer cells [25, 26], 
and to reduce tumor size in breast cancer in vivo [17]. 
We observed the most significant effect of VRK1 
knockdown on HCC cell growth in SK-Hep1 cells, 
which expressed the highest level of VRK1. Conversely, 
transient overexpression of VRK1 did not significantly 
affect SK-Hep1 cell proliferation. The smallest effect of 
VRK1 knockdown was on Hep3B cells, which expressed 
lowest levels of VRK1. Similarly, growth of THLE-2 
cells, a normal liver cell line expressing low levels of 
VRK1, was also not significantly affected by VRK 
knockdown. Thus the differential sensitivities of cells to 
VRK1 knockdown or overexpression appears to reflect 
differences in basal VRK1 levels.
Xenograft assays confirmed that depletion of 
VRK1 could suppress tumor growth in vivo. Both VRK1 
and Ki-67 have been identified within proliferating 
areas of squamous epithelium, and high levels of VRK1 
correlated positively with Ki-67 in head and neck 
squamous carcinomas [15]. Similarly, we showed here 
that VRK1-positive cells within tumors in mice co-located 
with Ki-67-positive cells. Furthermore, the number of 
Ki-67 positive cells was significantly lower in tumors 
derived from VRK1-depleted SK-Hep1 cells than tumors 
derived from intact SK-Hep1 cells. Taken together, 
these findings suggest that VRK1 expression affects 
the proliferation of tumor cells, that VRK1 knockdown 
suppresses HCC cell growth in vitro and in vivo, and that 
the extent of its effect differs depending upon the basal 
VRK1 level in HCC cells.
We found that siRNA-mediated depletion of VRK1 
caused G1 arrest in HCC cells, which is consistent with 
previous observations in H460 and H1299 lung cancer 
cells and MCF 10A mammary epithelial cells [17, 26]. 
VRK1 also had distinct functions during G2/M phase, 
including phosphorylation of proteins involved in 
regulating the nuclear envelope, chromatin condensation 
and Golgi fragmentation [3]. However, the number of cells 
in G2/M phase was unaffected by VRK1 depletion in an 
asynchronous cell population (Fig. 3A). This suggests 
that during cell cycle progression in HCC cells, VRK1 
function during G1/S phase may be more important than 
during G2/M phase, or other mitotic kinases such as the 
Aurora kinases and haspin may compensate for the loss 
of VRK1. Indeed, overexpression of Aurora A and B 
has been reported in HCC [27, 28]. Among SK-Hep1 
and SH-J1 cells, which normally express high levels 
of VRK1, VRK1 depletion with nocodazole treatment 
significantly increased numbers of G1-arrested cells, but 
this effect was not as significant in Hep3B cells, which 
express very low levels of VRK1 (Fig. 3C and 3D). 
Interestingly, the percentage of G1 gated cells gradually 
declined in VRK1-depleted Hep3B cells (Fig. 3C and 
3D), which implies VRK1 depletion led to delayed 
G1/S transition in Hep3B cells. These findings may be 
explained by the different genetic backgrounds of the 
three cell lines. As in an earlier study of Rb-null Hep3B 
cells [29], we failed to detect Rb proteins in Hep3B cell 
lysates (Fig. 4A). Because the accumulation of p-Rb by 
cyclin D and Cdk complexes could be a critical regulatory 
step for G1/S transition [22], the reduction in cyclin D1 
levels may not be as significant for G1/S phase transition 
in Rb-null cells as in Hep3B cells. Thus, the extent of 
its effect may be differently manifest, depending on the 
genetic background of the HCC cells. Levels of cyclin D1, 
p-Rb795 and p-Rb807/811 were all reduced in VRK1-depleted 
cells, which is consistent with an earlier report showing 
that cyclin D1 and p-Rb levels declined upon VRK1 
downregulation in fibroblasts [25]. The reduction in the 
levels of cyclin D1 was attributed to a decrease in its 
gene’s transcription, which was in turn related to decreased 
CREB phosphorylation in VRK1-depleted HCC cells. We 
also observed that both p21 and p27 were upregulated 
upon VRK1 knockdown, but that p53 levels were 
unchanged (Fig. 4A). VRK1 thus appears to regulate p21 
expression independently of p53, though the mechanism 
by which VRK1 affects expression of p21 and p27 remains 
to be clarified. Taken together, these findings indicate that 
VRK1 depletion causes arrest or delay of G1/S transition, 
leading to a significant increase in the HCC cell fraction 
in G1 phase. This suggests the retardation of HCC cell 
growth induced by VRK1 depletion reflects interference 
with the cell cycle.
We suggest that VRK1 is a potential therapeutic 
target for treatment of HCC, based on its levels in our 
clinical samples and its role in cell proliferation. It has also 
been proposed that in lung cancer and rhabdomyosarcoma, 
the VRK1 gene is a “druggable target gene” whose function 
in tumors is distinguishable from that in healthy tissue 
[26, 30]. In the present study, the VRK1 inhibitor luteolin 
effectively inhibited HCC cell proliferation. Although 
several kinase inhibitors have been shown to suppress 
VRK1 kinase activity, the inhibitory mechanism has not 
been determined [31]. Our group recently reported that 
luteolin specifically binds to the catalytic domain of VRK1 
to inhibit the kinase activity [32]. By inhibiting VRK1, 
luteolin reduced HCC cell growth in vitro and in vivo, and 
also induced apoptosis in HCC cells (Fig. 5C). Consistent 
with our results, the anti-cancer effects of luteolin have also 
been demonstrated in several HCC cell lines. For example, 
luteolin inhibited HGF-induced HepG2 cell invasion and 
mediated increases in intracellular ROS levels in Huh-7 
cells [33, 34]. In the present study, however, we did not 
observe significant induction of apoptosis upon VRK1 
depletion by VRK1 siRNA (Sup. Fig. 4). The extent of 
its different effect on apoptotic induction between VRK1 
inhibition with luteolin treatment and VRK1 depletion by 
VRK1 siRNA could be explained by multiple molecular 
target of luteolin [24] or/and the residual VRK1 expression 
in cells transfected with VRK1 siRNAs. Addressing this 
issue will require development of more specific and potent 
inhibitors of VRK1.
Aberrant VRK1 expression has been reported in 
colon cancer and lung cancer tissues [26, 35]. Similarly, 
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we observed higher levels of VRK1 in HCC tumor tissue 
and cell lines than in corresponding non-tumorous liver 
tissue and normal liver cells (Fig. 1A and Fig. 7E). VRK1 
expression is known to be dependent on the p53 status. 
Induction of p53 expression using UV light or transfection 
with the plasmid encoding p53 downregulated VRK1 
levels, which is consistent with the inverse correlation 
between VRK1 and p53 levels reported previously [12]. 
Moreover, VRK1 accumulated in lung tumors expressing 
mutant p53 with an altered regulatory loop [16]. In 
contrast to those earlier reports, we did not find an inverse 
correlation between VRK1 and p53 levels in HCC cell 
lines (Fig. 1A and Table 1); nonetheless, the regulation 
of VRK1 expression by p53 was apparent. For example, 
VRK1 levels were reduced by ectopic expression of p53 in 
HCC cells (Sup. Fig. 1), and VRK1 increased the stability 
of p53 by phosphorylating it on Thr 18, which inhibits p53 
binding to mdm2 [10, 36]. On the other hand, we detected 
no significant change in p53 levels in response to VRK1 
depletion in HCC cells (Fig. 4A). Under our experimental 
conditions, the cells were not physiologically stressed, 
which may make it more difficult to detect changes in p53 
levels related to VRK1 depletion.
An association between stronger VRK1 expression 
with shorter OS was previously observed in patients with 
estrogen receptor-positive breast cancer [20]. Kaplan-
Meier survival analysis showed that HCC patients 
expressing high levels of VRK1 likely experience shorter 
times of OS and DFS and a higher incidence of recurrence. 
A high VRK1 level was found to be a significant risk 
factor for recurrence, as were other common prognostic 
factors, including Edmonson grade, tumor size and tumor 
stage. In addition, moderate hazard ratios for OS and DFS 
were also found. It is noteworthy that the multivariate 
Cox analysis suggested that the VRK1 level could be 
an independent prognostic factor for recurrence with 
borderline significance (P = 0.056).
In sum, we found that VRK1 is up-regulated in 
HCC, and its increased expression is associated with 
poor prognosis. In vitro and in vivo studies indicate that 
depletion of VRK1 leads to G1 arrest and inhibition of 
HCC cell proliferation. In addition, VRK1 depletion may 
suppress cyclin D1 expression by downregulating CCND1 
transcription and activating p21 and p27 expression. 
Notably, luteolin, a VRK1 inhibitor, suppresses HCC 
tumor growth by inhibiting cell proliferation and inducing 
cell death. Taken together, these findings suggest that high 
VRK1 levels could potentially serve as an indicator of 
poor prognosis and/or a therapeutic target in HCC.
MATERIALS AND METHODS
Cell culture and WST-1 assay
The SK-Hep1, Hep3B, Huh-7, HepG2 and SNU449 
cell lines were obtained from the Korean Cell Line Bank 
(Korea). SH-J1 cells were provided by Dr. Dae-Ghon 
Kim (Medical School, Chonbuk National University) 
[37]. HCC cells were cultured at 37°C under 5% CO2 in 
DMEM supplemented with 10% FBS, 100 units/ml of 
penicillin and 100 μg/ml streptomycin. THLE-2 cell line 
was purchased from the American Type Culture Collection 
(USA). THLE-2 cells originated from human primary 
normal liver cells were plated on culture plates pre-coated 
with a solution containing 0.01 mg/mL fibronectin, 0.03 
mg/mL bovine collagen type I and 0.01 mg/mL bovine 
serum albumin dissolved in Bronchial Epithelium Basal 
Medium (BEBM, Lonza). THLE-2 cells were cultured at 
37°C under 5% CO2 in BEBM supplemented with BEGM 
SingleQuots (Lonza).
The effects of VRK1 overexpression or depletion on 
proliferation were measured using WST-1 assays. Culture 
medium was exchanged with medium containing WST-1 
reagent (Roche, 1:10 final dilution) at 0 and 72 h after 
transfection. After incubating cells for 90 min at 37°C, 
absorbance at 450 nm was measured using a microplate 
reader (Spectrafluor Plus, Tecan). The effect of luteolin 
on HCC cells was also assessed using WST-1 assays. 
Cells were plated and incubated in medium containing 
various concentrations of luteolin (30, 40 and 50 μM). 
After 24 h of treatment, the medium was replaced with 
medium containing WST-1 reagent, and the cells were 
incubated for 1 h at 37°C.
Colony formation assay
Cells were transfected with the indicated siRNAs. 
After 24 h of transfection, the cells were seeded at 
a density of 2 × 103 cells per well in 6-well dishes 
and transfected again 5 days later. Ten days after the 
initial transfection, cells were fixed for 5 min with 4% 
formaldehyde in PBS, washed with PBS, and stained 
for 1 h with 0.5% crystal violet in 25% methanol. Plates 
were then washed with PBS to remove excessive dye and 
photographed with a digital camera. Quantitative changes 
in clonogenicity were determined by extracting colonies 
with 20% acetic acid and measuring the absorbance at 
595 nm. For stable cell lines, 2 × 103 cells were plated, 
and cells were fixed and stained 10 days after plating.
Expression vectors and synthesis of siRNA
The VRK1 and p53 expression vectors were used 
as described previously [4, 38]. Small interfering RNA 
(siRNA) duplex targeting human VRK1 (siVRK1; catalog 
no. 16704) and control scrambled siRNA (siCont.; catalog 
no. SN-1003) were purchased from Ambion (USA) and 
Bioneer (Korea), respectively.
Real-time RT-PCR
Real-time RT-PCR was performed to measure 
the cyclin D1 mRNA levels in HCC cells as described 
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previously [39]. Briefly, total RNA was isolated from the 
HCC cells using a RNeasy mini kit (Qiagen) according to 
the manufacturer’s instructions, and reversely transcribed 
to cDNA using MMLV reverse transcriptase and the 
oligo(dT) primer kit (Solgent). Actin was used as the 
control gene. Real-time PCR was performed using SYBR 
Green I (Takara) and a Light-Cycler rapid thermal cycler 
(Roche Diagnostics). The primer sequences are shown 
in Supplementary Table 3. The relative VRK1 levels in 
HCC cells were determined using the 2-ΔΔCT method, as 
described [40].
Western Blot analysis
Western blot analysis was performed as described 
previously [41] using following antibodies: mouse anti-
VRK1 (Santa Cruz, sc-271062), goat anti-actin (Santa Cruz, 
sc-1615), rabbit anti-cyclin D1 (Santa Cruz, sc-753), rabbit 
anti-cyclin D2 (Santa Cruz, sc-181), rabbit anti-CREB 
(Cell signaling, 9198), rabbit anti-p-CREB (Cell signaling, 
9191), rabbit anti-p27 (Santa Cruz, sc-528), mouse anti-p21 
(Santa Cruz, sc-6246), rabbit anti-p-RbS795(Cell signaling, 
9301), mouse anti-p53 (Santa Cruz, sc-126) and rabbit 
anti-p-RbS807/S811(Cell signaling, 9308).
Cell cycle analysis
To analyze the progression of the cell cycle on 
asynchronous cell populations, 8 × 105 cells were seeded 
onto 6-well plates, transiently transfected with negative 
control or VRK1-specific siRNA and grown for 24 h. Cells 
were then collected by trypsinization, fixed in the fixation 
solution containing 70% ethanol and 0.5% Tween-20, 
washed in PBS containing 1% BSA, resuspended in 200 μl 
PBS containing 100 μg/ml RNase (Sigma) and 50 μg/mL 
propidium iodide (Sigma), incubated in the dark for 40 min 
at room temperature, and analyzed using the Canto II flow 
cytometer (BD Biosciences). Acquired data were analyzed 
using ModFit LT software (Verity Software House).
To synchronize the cells at G2/M phase, cells were 
exposed to nocodazole (50 ng/ml) at 24 h after transfection. 
After the indicated exposure times (Fig. 3C), flow cytometry 
were performed using the same procedure described above.
Cell death analysis
Apoptosis was measured using a FITC Annexin V 
Apoptosis Detection Kit (BD Biosciences, 556547). HCC 
cells were treated with selected concentrations of luteolin 
or transfected with the indicated siRNAs and stained with 
propodium iodide (PI) and Annexin-V FITC. The stained 
cells were analyzed using the Canto II flow cytometer (BD 
Biosciences).
Reagents
Lipofectamine 2000 (Invitrogen) was used 
to introduce expression vectors and siRNAs into 
cells. Luteolin and nocodazole were purchased from 
Santa Cruz and Sigma Aldrich, respectively.
Establishment of stable cell lines
Stable cell lines were established by transduction 
with lentiviral shRNA targeting VRK1 or scrambled 
control (Sigma). SK-Hep1 cells (1 × 105) were seeded 
onto 6-well plates and infected with lentiviral particles 
containing scrambled control shRNA or VRK1 shRNA 
clones 1 to 5 at a multiplicity of infection (MOI) of 2 
in DMEM containing 8 μg/ml polybrene (Sigma) in 
each well. After 1 day, the DMEM containing lentivirus 
was replaced with growth medium, and the cells were 
incubated for an additional 1 day. Puromycin (2 μg/ml; 
Invitrogen) was added to each well to select for cells 
expressing shRNA. Knockdown efficiency in each 
stable cell line was confirmed by Western blot analysis 
performed 2, 3, 4, 5 and 6 weeks after viral transduction 
(Fig. 2A and Sup. Fig. 2). The target sequences of the five 
shRNA clones are shown in Supplementary Table 4.
Xenograft assay
Five-week-old male nude mice were purchased from 
Orient Bio (Korea) and raised in a specific pathogen-free 
area within the animal facilities at POSTECH (Korea). All 
animals were handled according to Institutional Animal 
Care and Use guidelines of POSTECH. To compare tumor 
growth between established stable SK-Hep1 cell lines 
in vivo, 2 weeks after viral transduction, the established 
cells (5 × 106) were resuspended in serum-free DMEM with 
Matrigel basement membrane matrix (BD Biosciences) 
at a 1:1 ratio (total volume, 100 μl) and subcutaneously 
injected into the right and left flanks of nude mice. Tumor 
sizes were measured every 2 weeks using the Vernier 
caliper, and volumes were determined according to the 
formula L × S2 × 0.52, where L is the longest diameter and 
S the shortest diameter of the tumor. Mice were sacrificed 
8 weeks after injection and the solid tumors isolated.
The effect of luteolin on tumor growth in vivo was 
assessed using the method described previously [42] 
with minor modification. SK-Hep1 cells (1 × 107) were 
resuspended in serum-free DMEM with Matrigel basement 
membrane matrix (BD Biosciences) at a 1:1 ratio (total 
volume, 100 μl) and subcutaneously injected into the 
right flank of nude mice. Mice were then intraperitoneally 
administered vehicle or luteolin (20 mg/kg/d) daily from 
2 weeks after inoculation. The body weight and tumor size 
of each mouse were measured and tumor volumes were 
determined according to the formula L × S2 × 0.52, where 
L is the longest diameter and S the shortest diameter of 
the tumor.
Patients and tissue samples
HCC and surrounding non-tumor hepatic tissues 
were collected with informed consent from 88 HCC 
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patients who had undergone curative resection of primary 
HCCs between 1995 and 2007 at the Ajou Medical 
Center in Korea. The clinicopathological data for the 
88 patients, which are summarized in Supplementary 
Table 1, were almost entirely available in the medical 
records. Exceptions were the HBV status in one case, 
HCV status in two cases and AFP level in one case. BCLC 
stage, tumor stage, and Edmondson and Steiner grades 
were used according to published criteria. Liver function 
was preserved in all patients, and no patients died within 
2 months after surgery in the current cohort. The median 
follow-up time was 23.47 months (range, 1.15–134.30) for 
recurrence and DFS and 47.77 months (range, 2.01–193.68) 
for OS. Recurrence was defined as the first appearance of 
new lesions at any site after surgery, as confirmed using 
radiologic imaging. Patients who underwent local therapy, 
including transcatheter arterial chemoembolization and 
radiofrequency ablation, were not included. Fresh tumors 
and surrounding normal tissues were partly snap-frozen 
in liquid nitrogen immediately after hepatectomy and 
stored at −80°C. The study protocol was approved by the 
Institutional Review Board of the Ajou Medical Center.
Immunohistochemistry
Immunohistochemical detection of VRK1 in 
patient samples was performed using formalin-fixed and 
paraffin-embedded tissue sections (~4 μm thick). After 
deparaffinization in xylene for 15 min, rehydrated tissue 
sections were subjected to antigen retrieval by boiling in 
Tris-EDTA buffer (pH 9.0) for 5 min. Slides were then 
incubated with rabbit anti-VRK1 (Santa Cruz) for 1 h 
at room temperature, and the VRK1 antigen-antibody 
reaction was detected using a Real Detection System 
(Dako, K5001). Immunohistochemical intensity of VRK1 
staining was evaluated by two independent pathologists. 
VRK1 expression was evaluated in 10 high-power fields 
(400 ×). In each sample, intensity was classified as 
0 (negative staining), 1 (<5% staining), 2 (<25% staining), 
3 (25–50% staining) and 4 (>50% staining), and the 
average intensity assessed. Immunohistochemical 
detection of Ki-67 in mouse tumors treated with luteolin 
was also performed using the same method described 
above with mouse anti-Ki-67 (Dako, M7240) antibody.
Immunofluorescence
Solid tumors from mice were placed in formalin 
for paraffin block preparation. To verify Ki-67-positive 
and VRK1-positive cells in the same tumor section, solid 
tumor sections were incubated with mouse anti-Ki-67 
(Dako, M7240) and rabbit anti-VRK1 antibodies prepared 
as described [43]. Sections were subsequently washed 
with PBS containing 0.05% Tween-20 and incubated 
with anti-rabbit Alexa Fluor 594 (Invitrogen) and anti-
mouse Alexa Fluor 488 (Invitrogen) for 1 h at room 
temperature in the dark. Sections were then washed with 
PBS containing 0.05% Tween-20, incubated with Hoechst 
33342 (Invitrogen) for 2 min at room temperature and 
mounted with Mounting medium (Dako).
Hematoxylin and Eosin (H&E) Staining
Liver and tumor tissues from mice were fixed and 
embedded in paraffin and ~4-μm-thick were prepared. 
The sections were stained with H&E as described 
previously [44].
Statistical analysis
Relations between VRK1 protein levels and 
clinicopathological characteristics were evaluated using 
χ2 and Fisher’s exact tests. Tumor recurrence, OS and 
DFS were compared between VRK1-high and VRK1-low 
groups using the Kaplan–Meier method, and significant 
differences in curves was assessed using the log-rank 
test. Results of the WST-1 and colony forming assays, 
weight and volume of tumors, immunofluorescence 
intensities and real time RT-PCR were analyzed using 
Student’s t test. Cox regression analysis was performed to 
evaluate the prognostic significance of clinicopathological 
parameters and VRK1 expression. Values of P < 0.05 were 
considered statistically significant, and data marked with a 
one (*), two (**) or three (***) asterisks indicate P values 
of < 0.05, < 0.01 and < 0.001, respectively. Statistical 
analyses were performed using SPSS v. 18.0 (IBM) and 
the open source statistical program R v 3.1.1.
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